Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05MKN
|
|||
| Drug Name |
Azetidine urea derivative 3
|
|||
| Synonyms |
PMID26413912-Compound-51
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
JANSSEN PHARMACEUTICA NV BREITENBUCHER, Guy, J. TICHENOR, Mark, S. MERIT, Jeffrey, E. HAWRYLUK, Natalie, A. CHAMBERS, Alison, L. KEITH, John, M
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H23ClN4O3
|
|||
| Canonical SMILES |
C1C(CN1C(=O)NC2=CN=C3C(=C2)C=CN3)CCOC4=CC(=CC=C4)OC5=CC=C(C=C5)Cl
|
|||
| InChI |
1S/C25H23ClN4O3/c26-19-4-6-21(7-5-19)33-23-3-1-2-22(13-23)32-11-9-17-15-30(16-17)25(31)29-20-12-18-8-10-27-24(18)28-14-20/h1-8,10,12-14,17H,9,11,15-16H2,(H,27,28)(H,29,31)
|
|||
| InChIKey |
XAYGGDSGTNLICL-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fatty acid amide hydrolase (FAAH) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Fatty acid amide hydrolase (FAAH) | Target's Patent Info | [1] | |
| BioCyc | Anandamide degradation | |||
| KEGG Pathway | Retrograde endocannabinoid signaling | |||
| Panther Pathway | Anandamide degradation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.